Current and future use of dipyridamole in patients with COVID-19
https://doi.org/10.37489/2588-0519-2020-S4-92-95
Abstract
Current use of dipyridamole in COVID-19 is mainly based on its antithrombotic activity, since there is no robust clinical effectiveness data. The decision to use dipyridamole in COVID-19 should be individualized, considering the experimental nature of this treatment.
About the Authors
I. S. Burashnikova
Kazan State Medical Academy — Branch Campus of the Federal State Budgetary Educational Institution of Further Professional Education «Russian Medical Academy of Continuous Professional Education» of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Burashnikova Irina S. – Candidate of Medical Sciences, assistant of the Department of clinical pharmacology and pharmacotherapy. SPIN code: 4185-1810
Kazan
V. M. Tsvetov
Federal Center for Cardiovascular Surgery of the Ministry of Health of Russia
Russian Federation
Russian Federation
Tsvetov Vitaly M. – Candidate of Medical Sciences, Doctor — Clinical Pharmacologist. SPIN code: 3202-7659
Chelyabinsk
K. B. Mirzaev
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Mirzaev Karin B. – Candidate of Medical Sciences, Associate Professor of the Department of Clinical Pharmacology and Therapy. SPIN code: 8308-7599
Moscow
D. A. Sychev
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Sychev Dmitry A. – Doctor of Medical Sciences, Professor, Corresponding Member RAS, Rector, Head Department of Clinical Pharmacology and Therapy. SPIN code: 4525-7556
Moscow
References
1. Дипиридамол. Доступно по: https://grls.rosminzdrav.ru/ П N013897/01-280312
2. https://www.rceth.by/NDfiles/instr/3733_99_04_09_14_15_20_s.pdf
3. https://www.drugs.com/ppa/dipyridamole.html
4. Fauci AS, Lane HC, Redfield RR. COVID-19 — navigating the uncharted. N Engl J Med. 2020 Mar 26;382(13):1268-1269. DOI: 10.1056/NEJMe2002387
5. Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost. 2020 Jul;18(7):1559-1561. DOI: 10.1111/jth.14849
6. Balakumar P, Nyo YH, Renushia R et al. Classical and pleiotropic actions of dipyridamole: not enough light to illuminate the dark tunnel? Pharmacol Res. 2014 Sep;87:144-50. DOI: 10.1016/j.phrs.2014.05.008
7. Kim HH, Liao JK. Translational therapeutics of dipyridamole. Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):s39-42. DOI: 10.1161/ATVBAHA.107.160226
8. Guo S, Stins M, Ning M, Lo EH. Amelioration of inflammation and cytotoxicity by dipyridamole in brain endothelial cells. Cerebrovasc Dis. 2010 Aug;30(3):290-296. DOI: 10.1159/000319072
9. Renvert S, Lindahl C, Roos-Jansåker AM, Lessem J. Short-term effects of an anti-inflammatory treatment on clinical parameters and serum levels of C-reactive protein and proinflammatory cytokines in subjects with periodontitis. J Periodontol. 2009 Jun;80(6):892-900. DOI: 10.1902/jop.2009.080552
10. Macatangay B, Jackson E, Abebe K et al. A randomized, placebocontrolled, pilot clinical trial of dipyridamole to decrease human immunodeficiency virus-associated chronic inflammation. J Infect Dis. 2020 Apr 27;221(10):1598-1606. DOI: 10.1093/infdis/jiz344
11. Galabov AS, and Mastikova M. Dipyridamole induces interferon in man. Biomed Pharmacother. 1984;38(8):412-3.
12. Insel PA, Murray F, Yokoyama U et al. cAMP and Epac in the regulation of tissue fibrosis. Br J Pharmacol. 2012 May;166(2):447-56. DOI: 10.1111/j.1476-5381.2012.01847.x
13. Sanada S, Asanuma H, Koretsune Y et al. Long-term oral administration of dipyridamole improves both cardiac and physical status in patients with mild to moderate chronic heart failure: a prospective open-randomized study. Hypertens Res. 2007 Oct;30(10):913-919. DOI: 10.1291/hypres.30.913
14. Kuo K, Hung S, Tseng W et al. Dipyridamole decreases dialysis risk and improves survival in patients with pre-dialysis advanced chronic kidney disease. Oncotarget. 2017 Aug 3;9(4):5368-5377. doi: 10.18632/oncotarget.19850
15. Lee G, Choong H, Chiang G, Woo K. Three-year randomized controlled trial of dipyridamole and low-dose warfarin in patients with IgA nephropathy and renal impairment. Nephrology. 1997;3(1):117-121. DOI:10.1111/j.1440-1797.1997.tb00201.x
16. Tonew E, Indulen MK, Dzeguze DR. Antiviral action of dipyridamole and its derivatives against influenza virus A. Acta Virol. 1982 May;26(3):125-9.
17. Kuzmov K, Galabov AS, Radeva K et al. Epidemiological trial of the prophylactic effectiveness of the interferon inducer dipyridamole with respect to influenza and acute respiratory diseases. Zh Mikrobiol Epidemiol Immunobiol. 1985 Jun;(6):26-30.
18. Fata-Hartley CL, Palmenberg AC. Dipyridamole reversibly inhibits mengovirus RNA replication. J Virol. 2005 Sep;79(17):11062-70. DOI: 10.1128/JVI.79.17.11062-11070.2005
19. Tenser RB, Gaydos A, Hay KA. Inhibition of herpes simplex virus reactivation by dipyridamole. Antimicrob Agents Chemother. 2001 Dec;45(12):3657-9. DOI: 10.1128/AAC.45.12.3657-3659.2001
20. Szebeni J, Wahl SM, Popovic M et al. Dipyridamole potentiates the inhibition by 3’-azido-3’-deoxythymidine and other dideoxynucleosides of human immunodeficiency virus replication in monocyte-macrophages. Proc Natl Acad Sci USA. 1989 May;86(10):3842-6. DOI: 10.1073/pnas.86.10.3842
21. Kozhukharova MS, Slepushkin AN, Radeva KhT et al. Evaluation of dipyridamole efficacy as an agent for preventing acute respiratory viral diseases. Vopr Virusol. May-Jun 1987;32(3):294-7
22. Hu X, Wang X. Treatment of viral upper respiratory tract infection in children with dipyridamole. Chin J Hosp Pharm, 15 (1995), p. 401
23. Sui Y. Clinical observation of 45 cases of upper respiratory tract infection treated with dipyridamole. Publ Med Forum Mag, 18 (2014), pp. 4360-4361
24. Xie H. Efficacy of dipyridamole in the treatment of 116 children with acute upper respiratory tract infections. Chin J Sch Doct. 24 (2010), p. 921.
25. Liu X, Li Z, Liu S et al. Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction. Medrxiv. Posted February 29, 2020. DOI:10.1101/2020.02.27.20027557
26. Liu X, Li Z, Liu S et al. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19. Acta Pharm Sin B. 2020 Jul;10(7):12051215. DOI: 10.1016/j.apsb.2020.04.008
27. COVID-19 treatment Protocol at MSU medical center. (In Russ). Доступно по: http://mc.msu.ru/protokol-COVID-MNOC.pdf
Review
For citations:
Burashnikova I.S., Tsvetov V.M., Mirzaev K.B., Sychev D.A. Current and future use of dipyridamole in patients with COVID-19. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2020;(4S):92-95. (In Russ.) https://doi.org/10.37489/2588-0519-2020-S4-92-95
Views:
11756
Email this article 